Neil H. Segal, MD
Combination strategies could provide an opportunity to extend the utility of immunotherapy to more patients with colorectal cancer (CRC), according to Neil H. Segal, MD, PhD.
Currently, immunotherapy is approved for use in the second-line setting for patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) CRC. In May 2017, the FDA granted an accelerated approval to pembrolizumab
(Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H/dMMR solid tumors that have progressed after prior therapy and who have no alternative treatment options, as well as for those with MSI-H/dMMR CRC following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
... to read the full story